PROBIOTEC LIMITED

ABN 91 075 170 151

83 CHERRY LANE, LAVERTON NORTH, VIC 3026

ASX ANNOUNCEMENT

5 February 2020

HALF YEAR TRADING UPDATE

Probiotec Limited (ASX: PBP) ("Probiotec" or "the Company") is pleased to announce that the Company expects to report EBITDA from continuing operations for the half year ending 31 December 2019 of approximately $6.2 million1, an increase on the prior corresponding period of 68%. Revenue from continuing operation for the half year was up 34% to $44.1 million.

In the absence of any unforeseen events and subject to normal trading conditions, the board reaffirms its full year forecast of revenues to exceed $100 million and EBITDA in the range of $16 to $17 million for FY20 as previously announced on 1 July 2019.

Pleasingly, the Company is continuing to receive solid levels of enquiries and sales leads and is well positioned to capitalise on these opportunities with significant capacity available as a result of recent investments.

Wes Stringer, CEO of Probiotec stated 'we are pleased that we have continued to execute with respect to the delivery on the existing portfolio of the business as well as the ongoing integration of our recent acquisitions.'

The half year results for the Company are scheduled for release on 24 February 2020.

---ends---

1 Final figures are subject to half year review, which is currently in progress by the Company's auditors. Figures exclude non-recurring transaction costs incurred during the half year.

PROBIOTEC LIMITED

ABN 91 075 170 151

83 CHERRY LANE, LAVERTON NORTH, VIC 3026

About Probiotec

Probiotec Limited is a manufacturer, packer and distributor of a range of prescription and over-the-counter (OTC) pharmaceuticals, complementary medicines and consumer health products. The company owns three manufacturing facilities in Australia and distributes its products both domestically and internationally. Products are manufactured by Probiotec on behalf of a range of clients, including major international pharmaceutical companies.

Further details about Probiotec are available at www.probiotec.com.au

Authorised for release to the ASX by:

Wes Stringer

Managing Director

Ph: (03) 9278 7555

For further information contact:

Wes Stringer

Managing Director

Ph: (03) 9278 7555

Attachments

  • Original document
  • Permalink

Disclaimer

Probiotec Limited published this content on 05 February 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 February 2020 03:08:07 UTC